This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe
Europe's premier partnering event
Save the date for next yearNovember 3–5, 2025 | Vienna, Austria
Menu

Jonathan Ward
CEO at Theratrame S.A.
Presenter

Profile

THERAtRAME discovers and develops new small molecule inhibitors targeting the tRNA epitranscriptomics to cure patients with untreatable cancer. The THERAtRAME discovery platform integrates unique sets of technologies to discover, develop and position new drugs to beat reluctant cancers. tRNA epitranscriptomics represents a new promising area for drug discovery in oncology. THERAtRAME ambitions to become a leader in the development and positioning of novel cancer therapies.

Agenda Sessions

  • “Take a Chance on Me”: Startup spotlight pitch competition

    , 15:00
    View Session

At this event

Prev
Next
Mike Ward
Global Head of Thought Leadership
Decision Resources Group, part of Clarivate

See Jonathan at BIO-Europe